您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2014, Vol. 52 ›› Issue (8): 52-56.doi: 10.6040/j.issn.1671-7554.0.2013.701

• 临床医学 • 上一篇    下一篇

基于莫西沙星和埃索美拉唑镁的三联疗法对幽门螺旋杆菌根除效果的临床观察

王慧   

  1. 山东工商学院医院消化内科, 山东 烟台 264005
  • 收稿日期:2013-11-22 修回日期:2014-07-03 出版日期:2014-08-10 发布日期:2014-08-10
  • 通讯作者: 王慧。E-mail:gpcwh@sina.com E-mail:gpcwh@sina.com

Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori

WANG Hui   

  1. Department of Gastroenterology, Hospital of Shandong Institute of Business and Technology, Yantai 264005, Shandong, China
  • Received:2013-11-22 Revised:2014-07-03 Online:2014-08-10 Published:2014-08-10

摘要: 目的 评价基于莫西沙星和埃索美拉唑镁的三联疗法对初治幽门螺旋杆菌(Hp)感染的根除效果。方法 将126例患者分为莫西沙星组和对照组,莫西沙星组给予莫西沙星、埃索美拉唑镁、克拉霉素;对照组给予奥美拉唑、阿莫西林、克拉霉素,疗程均为2周。治疗结束1个月后进行内镜检查(活组织病理学检查)和快速尿素酶试验以及13碳/14碳尿素酶呼气试验(13C/14C-UBT),比较药物不良反应及依从性情况。结果 莫西沙星组与对照组按意向治疗(ITT)Hp根除率分别为75.0%和58.1%(P<0.05);按符合方案(PP)Hp根除率分别为92.3%和69.2%(P<0.05)。不良反应和药物依从性比较,两组差异均无统计学意义(P>0.05)。结论 基于莫西沙星和埃索美拉唑镁的三联疗法对初治Hp感染有较高根除率,药物不良反应和依从性与标准三联疗法无差异,可考虑作为一线治疗方案。

关键词: 莫西沙星, 埃索美拉唑镁, 联合, 幽门螺旋杆菌, 药物疗法

Abstract: Objective To evaluate the efficacy of triple therapy of moxifloxacin and esomeprazole magnesium to eradicate Helicobacter pylori (Hp). Methods A total of 126 patients were randomly divided into moxifloxacin group and control group. The moxifloxacin group was treated with moxifloxacin, esomeprazole and clarithromycin, while the control group was treated with omeprazole, amoxicillin and clarithromycin. Both treatments lasted for 2 weeks. One month after the treatment, the patients undertook endoscopic examination (pathological biopsy), rapid urease test and 13carbon/14 carbon urea breath test (13C/14C-UBT). The adverse drug reactions and compliance were observed. Results In intention to treat (ITT)analysis, the Hp-eradication rate was 75.0% in the moxifloxacin group, and 58.1% in the control group (P<0.05); in per protocol (PP) analysis, the Hp-eradication rate was 92.3% in the moxifloxacin group, and 69.2% in the control group (P<0.05). However, in the adverse drug reaction and compliance comparison analysis, there was no statistical difference between the two groups (P>0.05). Conclusion The triple therapy based on moxifloxacin and esomeprazole is highly effective to eradicate Hp infection, with no significant difference in the adverse drug reaction and compliance from the conventional triple therapy; therefore, it is worth of clinical spread.

Key words: Combination, Helicobacter pylori, Drug therapy, Moxifloxacin, Esomeprazole magnesium

中图分类号: 

  • R573
[1] 董玉柱.以莫西沙星、埃索美拉唑镁为核心的三联疗法治疗一线、补救治疗失败的幽门螺杆菌感染的临床观察[J].临床合理用药杂志,2011,4(2):8-9.
[2] 许静,高日金,孟云霞,等. 埃索美拉唑配合莫西沙星和克拉霉素根除幽门螺旋杆菌疗效观察[J].内蒙古中医药,2011,30(14):92-93.
[3] 詹春光,李健.莫西沙星三联疗法根除幽门螺杆菌感染的临床研究[J].实用医学,2010,26(6):1032-1033.
[4] 中华医学会消化病学分会幽门螺杆菌学组/幽门螺杆菌科研协作组.第三次全国幽门螺杆菌感染若干问题共识报告[J].胃肠病学,2008,13(1):42-46.
[5] 辛磊,李兆申.氯吡格雷与质子泵抑制剂联合应用的不良反应研究进展[J].中华内科,2010,49(10):899-890.
[6] 周丽丽. 质子泵抑制剂致不良反应因素分析[J].中国药业,2013,22(10):899-890.
[7] 王承党,庄则豪,陆岽,等.含莫西沙星三联方案根除幽门螺杆菌的疗效观察[J].中华医学,2010,90(2):87-89.
[8] Bago J, Pevec B, Tomic' M, et al. Second-1ine treatment for Helicobacter pylori infection based on moxifloxaein triple therap: a randomized controlled trial[J]. Wien Klin Wochenschr, 2009, 121(1-2):47-52.
[9] 李娜,聂占国. 幽门螺旋杆菌对抗生素耐药现状及其机制研究进展[J].山东医药,2013,53(16):85-88.
[10] Rimbar E, Noguchi N, Kawai T, et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB[J]. Helicobacter, 2012, 17(1):36-42.
[11] Cattoir V, Nectoux J, Lascols C, et al. Update on fluroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first descrip tion of a gyrApolymorphism associated with hypersusceptibility[J]. Int J Antimicrob Agents, 2007, 29(4):389-396.
[12] 郑小丽,许乐. 含莫西沙星三联疗法对幽门螺杆菌根除失败的补救治疗[J].中华医学,2010,90(2):83-86.
[13] 黄秀萍,黄荣富,钟能能,等.质子泵抑制剂的应用分析[J].临床合理用药,2011,4(12A):60-61.
[14] Sugimoto M, Nishino M, Kodaira C, et al. Characteristics of nonerosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy[J]. World J Gastroenterol, 2011, 17(14):1858-1865.
[15] Malfertheiner P, Megraud F, O'Morain C, et al. Current concepta in the management of Helicobacter pylori infection: the Maastricht III Consensus Report[J]. Gut,2007, 5(6):772-781.
[16] 肖琼怡,王建刚,刘海,等.莫西沙星三联方法根除幽门螺杆菌的成本-效果分析[J].山西医药,2010,39(3):270-271.
[1] 赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 131I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28.
[2] 王锐,张伟,初竹秀,郭琳琳,王倩,葛丽丽,石配,王永梅. 经胸右心声学造影联合对比增强经颅多普勒对卵圆孔未闭右向左分流的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(2): 36-41.
[3] 毛倩,王喆,管佩霞,刘玉洁,肖宇飞,杨毅,丛慧文,王廉源,石福艳,王素珍. 1 144例尿酸测值动态变化与痛风发病的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(8): 107-112.
[4] 王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.
[5] 杨贵霞,徐阳,马明明,宋然,朱鹏飞. 宫腹腔镜联合治疗Robert子宫合并子宫腺肌病1例[J]. 山东大学学报 (医学版), 2021, 59(1): 122-124.
[6] 肖宇飞,冯佳宁,王晓璇,毛倩,石福艳,王素珍. 利用数据库数据采用联合模型动态预测312例肝硬化患者预后的观察分析[J]. 山东大学学报 (医学版), 2020, 1(9): 71-76.
[7] 王刚,江志伟,潘华峰. 经腹会阴联合切除术的回顾与发展[J]. 山东大学学报 (医学版), 2020, 58(5): 6-10.
[8] 王海锋,王刚,赵健,刘江,周嘉晖,江志伟. 加速康复外科在直肠癌腹会阴联合切除术中的应用[J]. 山东大学学报 (医学版), 2019, 57(9): 33-37.
[9] 刘发生,韩建,李莎,尚红园,马敏,王荣春,张爱平,韩利文. 纳米TiO2联合Cu2+对斑马鱼胚胎发育毒性的影响[J]. 山东大学学报 (医学版), 2018, 56(7): 33-38.
[10] 贾忠兰,许丽风. 液体-固体联合培养法检测泌尿生殖道支原体的临床研究[J]. 山东大学学报 (医学版), 2018, 56(10): 110-113.
[11] 李安, 陈丰哲,王正,孟祥珠,许楠楠,马立宪. 西他沙星、头孢哌酮/舒巴坦和多黏菌素E单药及联合用药对泛耐药鲍曼不动杆菌的抗菌活性[J]. 山东大学学报(医学版), 2017, 55(4): 82-85.
[12] 徐志宏,刘荣凤,王晓翔,冯莉,姚铁柱,刘红. 养正消积胶囊联合化疗治疗转移性乳腺癌的临床疗效及安全性[J]. 山东大学学报(医学版), 2016, 54(5): 79-83.
[13] 崔勇, 张荣香, 王福立, 王国颖, 冯建林, 张海霞. BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果[J]. 山东大学学报(医学版), 2015, 53(7): 53-57.
[14] 费志强, 龚淇, 张华. 幽门螺旋杆菌感染与胃息肉患者血清或组织中HIF-1α的相关性[J]. 山东大学学报(医学版), 2015, 53(6): 63-67.
[15] 白翠兰, 长春, 白金亮, 辛颖. 蒙药胃舒安中挥发性成分药材对 幽门螺旋杆菌及其相关酶活性抑制作用的研究[J]. 山东大学学报(医学版), 2014, 52(S2): 7-8.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!